Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Randomized, Placebo-controlled, Double-blind, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of PHP-201 in Patients With Primary Open-angle Glaucoma or Ocular Hypertension

NCT04863365 is registered in ClinicalTrials.gov with pH Pharma as lead sponsor.

NCT NCT04863365
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04863365 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Randomized, Placebo-controlled, Double-blind, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of PHP-201 in Patients With Primary Open-angle Glaucoma or Ocular Hypertension
Lead sponsor
pH Pharma
Phase
Phase 3
Overall status
Unknown status
Start date
November 30, 2021
Completion date
November 30, 2023
Enrollment
110 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ocular hypertension, primary open angle glaucoma